« Back
Home /
Nilotinib

Nilotinib

Item no.	HY-10159-200mg
Manufacturer	MedChem Express
CASRN	641571-10-0
Amount	200 mg
Quantity options	100 mg 10 mM/1 mL 200 mg 500 mg
Category	Oncology Metabolism Diabetes Glucose Homeostasis Inhibitors & Compound Libraries Small Molecules By Organ Colorectal Cancer Heart & Blood Cancer Gastric Cancer
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.94
Formula	C28H22F3N7O
Citations	ACS Chem Biol. 2016 Apr 15;11(4):992-1000. Biomaterials. 16 September 2022. Biomed Chromatogr. 2019 Dec;33(12):e4674. Biomolecules. 2022 Jun 11;12(6):819. bioRxiv. 2024 May 8:2024.05.07.592424. Br J Cancer. 2021 Nov 24. Breast Cancer Res. 2023 May 5;25(1):51. Cancer Biol Ther. 2019;20(6):877-885. Cancer Lett. 2024 Aug 1:217150. Cancer Med. 2016 Nov;5(11):3223-3234. Cancer Res. 2024 Oct 22. Cell Death Dis. 2021 Sep 25;12(10):875. Cell Mol Immunol. 2024 Aug;21(8):856-872. Cell Syst. 2018 Apr 25;6(4):424-443.e7. Diseases. 2023 Oct 23;11(4):147. Eur J Pharmacol. 2021 Feb 10;173944. Glia. 2022 Feb 13. Harvard Medical School LINCS LIBRARY Int J Mass Spectrom. 442 (2019) 44-50. J Pharm Sci. 2017 Sep;106(9):2632-2641. Leuk Lymphoma. 2015;56(8):2416-23. Oncotarget. 2018 Apr 24;9(31):22158-22183. Patent. US20190084960A1 Patent. US20210299273A1. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Stem Cell Reports. 2019 May 14;12(5):996-1006. Target Oncol. 2020 Oct;15(5):659-671. Technical University of Munich. 24.01.2018. Toxicol Lett. 2022 Jun 6;S0378-4274(22)00117-5. Toxicology. 2024 May 15:505:153830. Xenobiotica. 2018 Oct;48(10):1059-1071. bioRxiv. January 25, 2022. Cell Rep Methods. 2023 Oct 23;3(10):100599. Drug Metab Pharmacokinet. 2020 Feb;35(1):102-110. [1]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109(5):2112-20. [2]Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9(9):e107613. [3]Dervis Hakim G, et al. Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: A rat model. World J Gastroenterol. 2015 Nov 28;21(44):12576-85. [4]Fujita KI, et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites. J Pharm Sci. 2017 Sep;106(9):2632-2641. [5]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9(31):22158-22183.
Smiles	O=C(NC1=CC(C(F)(F)F)=CC(N2C=NC(C)=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	AMN107
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Autophagy; Bcr-Abl
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	529.52
Product Description	Nilotinib is an orally available Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
Manufacturer - Research Area	Cancer
Solubility	DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Autophagy; Protein Tyrosine Kinase/RTK
Clinical information	Launched

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-10159-200mg-safety-datasheet.pdf